Safety outcomes of Alteplase among acute ischemic stroke patients with special characteristics
- 110 Downloads
Although tissue plasminogen activator (tPA) has been approved for use in acute ischemic stroke, concerns linger regarding its safety. We analyzed whether patients in special subgroups (i.e., age >70 years, baseline National Institute of Health Stroke Scale (NIHSS) score >20, diabetes, congestive heart failure (CHF), and of Hispanic origin) have a higher risk of symptomatic intracerebral hemorrhage (SICH) than patients without these characteristics.
Four prospective observational studies of acute ischemic stroke patients treated within 3 h with Alteplase were identified and individual patient data were pooled for this analysis. These included the Standard Treatment with Alteplase to Reverse Stroke Study [STARS, N = 389], Epidemiology Study of Ischemic Stroke [ESIS, N = 236], University Of Texas Houston Stroke Study [UT, N = 241], and Canadian Activase For Stroke Effectiveness Study [CASES, N = 1100]. The risk of SICH was calculated for all patients and for each of five subgroups.
A total of 1966 patients were studied. Overall the risk of symptomatic ICH was 4.7% (95%CI, 3.8–5.8%) and the risk was similar among patients with and without each of the five characteristics. Patients with advanced age, baseline NIHSS score >20, CHF or diabetes had increased mortality and significantly lower rate of functional recovery.
The present study suggests that these specified subgroups of patients are not at increased risk of SICH after stroke thrombolysis compared to those without these characteristics.
KeywordsThrombolysis Tissue plasminogen activator Acute ischemic stroke
Unable to display preview. Download preview PDF.
- 4.The NINDS t-PA Stroke Study Group. Intracerebral hemorrhage after intravenous t-PA therapy for ischemic stroke. Stroke 1997;28:2109–18.Google Scholar
- 6.Hill MD, Buchan AM, for the Canadian Alteplase for Stroke Effectiveness Study (CASES) Investigators. Thrombolysis for acute ischemic stroke: results of the Canadian Alteplase for Stroke Effectiveness Study. CMAJ 2005;172:1307–12.Google Scholar
- 7.Okada Y, Yamaguchi T, Minematsu K, Miyashita T, Sawada T, Sadoshima S et␣al. Hemorrhagic transformation in cerebral embolic stroke. Stroke 1989;20:589–603.Google Scholar
- 8.Tanne D, Kasner SE, Demchuk AM, Koren-Morag N, Hanson S, Grond M et␣al. Markers of increased risk of intracerebral hemorrhage after intravenous recombinant tissue plasminogen activator for acute ischemic stroke in clinical practice: the Multicenter rt-PA Acute Stroke Survey. Circulation 2002;105:1679–85.PubMedCrossRefGoogle Scholar
- 9.Gurwitz JH, Gore JM, Gold berg RJ, Barron HV, Breen T, Rundle AC et␣al. Risk for intracranial hemorrhage after tissue plasminogen activator treatment for acute myocardial infarction: participants in the national registry of myocardial infarction 2. Ann Intern Med 1998;129:597–604.PubMedGoogle Scholar
- 15.Kase CS, Furlan AJ, Wechsler LR, Higashida RT, Rowley HA, Hart RG et␣al. and PROACT II investigators. Cerebral hemorrhage after intra-arterial thrombolysis for ischemic stroke. the PROACT II trial. Neurology 2001;57:1603–10.Google Scholar